Transthyretin Amyloid Cardiomyopathy (attr-Cm) Clinical Trials
2 recruiting trials for Transthyretin Amyloid Cardiomyopathy (attr-Cm). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Transthyretin Amyloid Cardiomyopathy (attr-Cm) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Bayer (1), AstraZeneca (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Acoramidis (356 mg film-coated tablets) (drug, 1 trial), followed by Eplontersen, ALXN2220.
Track Transthyretin Amyloid Cardiomyopathy (attr-Cm) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid...
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in...
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen...
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Transthyretin Amyloid Cardiomyopathy (attr-Cm), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Transthyretin Amyloid Cardiomyopathy (attr-Cm), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Transthyretin Amyloid Cardiomyopathy (attr-Cm), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.